ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

This week’s episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).

Episode metadata supplied by the publisher feed · Published Dec 16, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL

0:00 11:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Two Onc Docs?

This episode is 11 minutes long.

When was this Two Onc Docs episode published?

This episode was published on December 16, 2025.

Can I download this Two Onc Docs episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!